Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Key facts
- Who runs it
- Chinese PLA General Hospital
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 146 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lenalidomide
- Placebo
- Record updated
- 22 July 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults aged 18 to 75 years at the time of screening
- Diagnosis of IgG4-related disease according to the 2019 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria
- Patients with IgG4-related disease who have achieved sustained clinical remission following glucocorticoid therapy
- No documented IgG4-related disease relapse within the previous 12 months before screening
- IgG4-related disease Responder Index (IgG4-RD RI) score of 0 at screening
- Receiving stable low-dose glucocorticoid therapy with prednisone-equivalent dose ≤7.5 mg/day for at least 6 months before randomization
- Ability to provide written informed consent and comply with study procedures
Who cannot take part
- Previous treatment with lenalidomide or known hypersensitivity to lenalidomide or related compounds
- Requirement for prohibited concomitant medications during the study period
- Significant hepatic or renal dysfunction that may affect study participation or drug safety evaluation
- Active IgG4-related disease requiring induction therapy or escalation of immunosuppressive treatment at screening
- Significant uncontrolled infection or active severe infection
- History of thromboembolic events or conditions associated with unacceptable thrombotic risk according to investigator assessment
- Malignancy or other severe medical conditions that may interfere with study participation or outcome assessment
- Any condition that, in the investigator's opinion, may compromise participant safety or affect the reliability of study results
- Clinically significant hematologic abnormalities, including severe neutropenia or thrombocytopenia
- Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs. Although glucocorticoids can effectively induce remission, many patients experience disease relapse after glucocorticoid tapering or discontinuation, and long-term glucocorticoid exposure may cause significant adverse effects. Therefore, new maintenance treatment strategies are needed to reduce relapse risk and minimize glucocorticoid-related toxicity.
Read full original descriptionShow less
This study is designed to evaluate the efficacy and safety of lenalidomide as a maintenance therapy in patients with stable IgG4-RD. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.
Eligible participants will be adults with IgG4-RD who meet the 2019 ACR/EULAR IgG4-RD classification criteria and are in a stable disease state. Participants will be randomly assigned in a 1:1 ratio to receive either lenalidomide or matching placebo for 52 weeks. All participants will receive standardized glucocorticoid tapering according to the study protocol.
The primary objective of this study is to determine whether lenalidomide can reduce the risk of IgG4-RD relapse compared with placebo. The primary outcome is the proportion of participants experiencing disease relapse within 52 weeks after randomization.
Secondary objectives include evaluation of time to relapse, maintenance of remission, changes in disease activity, quality of life, and safety outcomes. Exploratory assessments will investigate changes in immunological biomarkers, peripheral blood immune profiles, transcriptomic characteristics, and gut microbiota.
This study aims to provide clinical evidence for a new maintenance treatment approach for patients with IgG4-RD and potentially reduce disease recurrence and glucocorticoid exposure.
The 2 groups in the trial
- Lenalidomide ArmTreatment being tested
Participants will receive lenalidomide 5 mg orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. Lenalidomide will be administered in addition to background glucocorticoid management.
Treatment: Lenalidomide
- Placebo ArmPlacebo, for comparison
Participants will receive matching placebo orally once daily for 52 weeks as maintenance therapy. All participants will undergo standardized glucocorticoid tapering according to the study protocol during the initial treatment period. The placebo will be identical in appearance, packaging, labeling, and administration procedures to lenalidomide.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Criteria questions
- Built from NCT07719543, who can take part
- Record updated
- 22 July 2026